Deferred Tax Assets, Valuation Allowance of aTYR PHARMA INC from 31 Dec 2013 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
aTYR PHARMA INC quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2013 to 31 Dec 2025.
  • aTYR PHARMA INC Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $142,194,000, a 15% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

aTYR PHARMA INC Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $142,194,000 +$18,011,000 +15% 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q4 2024 $124,183,000 +$16,194,000 +15% 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q4 2023 $107,989,000 +$12,505,000 +13% 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q4 2022 $95,484,000 +$11,372,000 +14% 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q4 2021 $84,112,000 +$9,466,000 +13% 31 Dec 2021 10-K 14 Mar 2023 2022 FY
Q4 2020 $74,646,000 +$2,944,000 +4.1% 31 Dec 2020 10-K 15 Mar 2022 2021 FY
Q4 2019 $71,702,000 +$4,773,000 +7.1% 31 Dec 2019 10-K 24 Mar 2021 2020 FY
Q4 2018 $66,929,000 +$7,203,000 +12% 31 Dec 2018 10-K 26 Mar 2020 2019 FY
Q4 2017 $59,726,000 -$11,423,000 -16% 31 Dec 2017 10-K 26 Mar 2019 2018 FY
Q4 2016 $71,149,000 +$22,830,000 +47% 31 Dec 2016 10-K 20 Mar 2018 2017 FY
Q4 2015 $48,319,000 +$13,473,000 +39% 31 Dec 2015 10-K 16 Mar 2017 2016 FY
Q4 2014 $34,846,000 +$13,553,000 +64% 31 Dec 2014 10-K 30 Mar 2016 2015 FY
Q4 2013 $21,293,000 31 Dec 2013 10-K 30 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.